Influence of Decompensated Heart Failure on Cardiac Acoustic Biomarkers: Impact on Early Readmissions
Open Access
- 16 October 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 7 (6) , 4198-4205
Abstract
Aims Preventing hospitalization by detecting early evidence of heart failure (HF) decompensation in an outpatient setting can improve patient's quality of life and reduce costs of care. The purpose of this study was to assess the value of cardiac acoustic biomarkers (CABs), a combination of cardiohaemic vibrations synchronized with ECG signals, and heart rate (HR) for detecting HF decompensation during first 3 months after hospital discharge for HF. Methods and results Patients with an ejection fraction ≤35% (HFrEF) and hospitalized for decompensated HF were enrolled in a prospective observational study. All subjects wore a wearable cardioverter‐defibrillator (ZOLL LifeVest®, Pittsburgh, PA, USA) that is capable of recording CABs and HR. The primary endpoint of the study was the first HF event, defined as HF readmission or HF emergency room visit. From June 2017 through August 2019, 671 patients with HFrEF were enrolled. Eighty‐one patients (12.1%) had a total of 112 HF events. The algorithm detected HF events with a median of 32 days (interquartile range = 11‐45) in advance of the first HF event. The algorithm had a sensitivity of 69%, specificity of 60%, positive predictive value of 19%, and a negative predictive value of 94%. Of note, the baseline (first 7 days post‐enrolment) algorithm using CABs and HR was superior to New York Heart Association classification in detecting patients more likely to have HF decompensation (sensitivity and specificity of 61% and 68% vs. 46% and 55%, respectively). Conclusions This prospective international registry showed that an algorithm incorporating CABs and HR data detected HF events 30 days in advance of the event in patients with HFrEF during first 3 months after hospital discharge. Therefore, integrating CAB technology into clinical practice may prevent HF rehospitalizations.Keywords
Funding Information
- ZOLL Medical Corporation
- ZOLL Medical Corporation
This publication has 27 references indexed in Scilit:
- Wearable Cardioverter-DefibrillatorsCirculation, 2013
- Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or PneumoniaJAMA, 2013
- Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart FailureCirculation: Heart Failure, 2012
- Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trialEuropean Heart Journal, 2011
- Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart FailureCirculation, 2010
- Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD)Pacing and Clinical Electrophysiology, 2010
- Recent National Trends in Readmission Rates After Heart Failure HospitalizationCirculation: Heart Failure, 2010
- Transition From Chronic Compensated to Acute Decompensated Heart FailureCirculation, 2008
- The effect of treatment on the presence of abnormal heart sounds in emergency department patients with heart failureThe American Journal of Emergency Medicine, 2006
- Use of a Wearable Defibrillator in Terminating Tachyarrhythmias in Patients at High Risk for Sudden Death:Pacing and Clinical Electrophysiology, 2004